• Home
• Investors
• Annual Review 2005
• Shareholder information

Corporate governance

FINANCIAL REPORTING

Financial reporting calendar 2006

Announcement of 1st Quarter Results	April 2006
Announcement of 2nd Quarter Results	July 2006
Announcement of 3rd Quarter Results	October 2006
Preliminary Announcement of Annual Results	February 2007
Publication of Annual Report/Review	March 2007

Results Announcements

Results Announcements are issued to the London Stock Exchange and are available on its news service. Shortly afterwards, they are issued to the media, are made available on the website and are submitted to the US Securities and Exchange Commission and the New York Stock Exchange.

Financial reports

The company publishes an Annual Report and, for the investor not needing the full detail of the Report, an Annual Review. These are available on the website. The Annual Review is sent to all shareholders on the date of publication. Shareholders may also elect to receive the Annual Report by writing to the company's registrars. Alternatively, shareholders may elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk. Copies of previous financial reports are available on the website. Printed copies can be obtained from the registrar in the UK and from the Customer Response Center in the USA.

Publications

In late March 2006 GSK will publish on the website its Corporate Responsibility Report covering performance in areas including community investment, ethics and integrity, access to medicines, R&D, environment and health and safety.

SHARE PRICE

The table above sets out the middle market closing prices derived from the London Stock Exchange Daily Official List. The company's share price increased by 20% in 2005 from a price of £12.22 at 1st January 2005 to £14.69 at 31st December 2005. This compares with an increase in the FTSE 100 index of 17% during the year.

Market capitalisation

The market capitalisation of GSK at 31st December 2005 was £85 billion. At that date GSK was the fourth largest company by market capitalisation on the FTSE index.

DIVIDENDS

GSK pays dividends quarterly.

The Board has declared dividends for 2005 as follows:

As a guide to holders of ADRs, the table below sets out the dividends paid per ADS in US dollars in the last five years translated into US dollars at applicable exchange rates.

Dividend calendar

Fourth quarter 2005
Ex-dividend date	15th February 2006
Record date	17th February 2006
Payable	6th April 2006
First quarter 2006
Ex-dividend date	10th May 2006
Record date	12th May 2006
Payable	6th July 2006
Second quarter 2006
Ex-dividend date	2nd August 2006
Record date	4th August 2006
Payable	5th October 2006
Third quarter 2006
Ex-dividend date	1st November 2006
Record date	3rd November 2006
Payable	4th January 2007

ANNUAL GENERAL MEETING 2005

The Annual General Meeting will be held at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1P 3EE on 17th May 2006.

CAUTIONARY STATEMENT

Under the ‘safe harbor’ provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward looking statements or projections made by the company, including those made in this Annual Review, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group’s operations are described under ‘Legal proceedings’ and ‘Risk factors’ in the company’s Annual Report 2005.

SMITHKLINE BEECHAM PLC FLOATING RATE UNSECURED LOAN STOCK 1990/2010

The loan stock is not listed on any exchange but holders may require SmithKline Beecham plc to redeem their loan stock at par, i.e. £1 for every £1 of loan stock held, on the first business day of March, June, September and December. Holders wishing to redeem all or part of their loan stock should complete the notice on the back of their loan stock certificate and return it to the registrar, to arrive at least 30 days before the relevant redemption date.

SHARE BUY-BACK PROGRAMME

A total of £6.5 billion has been spent by the company since 2001 on buying its own shares for cancellation or to be held as Treasury shares, of which £1 billion was spent in 2005. The programme covers purchases by the company of shares for cancellation or to be held as Treasury shares, in accordance with the authority given by shareholders at the AGM in 2005.

In May 2005 the company was authorised to purchase a maximum of 586.4 million shares. During 2005 72.8 million shares were purchased and held as Treasury shares (see Note 31 to the financial statements, ‘Share capital and share premium account’ in the Annual Report 2005). The exact amount and timing of future purchases, and the extent to which repurchased shares will be held as Treasury shares rather than being cancelled, will be determined by the company and is dependent on market conditions and other factors.

INTERNET

Information about the company, including details of the share price, is available on GSK’s website at www.gsk.com

Information made available on the website does not constitute part of this Annual Review.

TRADEMARKS

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GSK or associated companies, with the exception of Boniva/Bonviva, a trademark of Roche, Entereg, a trademark of Adolor Corporation, and Nicoderm, a trademark of Sanofi-Aventis, Elan, Novartis or GSK in certain countries, all of which are used in certain countries under license by the Group.

INVESTOR RELATIONS

Investor Relations may be contacted as follows:

UK
980 Great West Road, Brentford, Middlesex TW8 9GS
Tel:  +44 (0)20 8047 5557/5558
Fax +44 (0)20 8047 7807

USA
One Franklin Plaza, PO Box 7929, Philadelphia PA 19101
Tel: 1 888 825 5249 toll free
Tel: +1 215 751 4638 outside the USA
Fax: +1 919 315 3344

ORDINARY SHARES

The company’s shares are listed on the London Stock Exchange (LSE).

Registrar

The company’s registrars are:

Lloyds TSB Registrars
The Causeway, Worthing, West Sussex BN99 6DA
www.shareview.co.uk
Tel: 0870 600 3991 inside the UK
Tel: +44 (0)121 415 7067 outside the UK

The registrars also provide the following services:

• GlaxoSmithKline Investment Plan

• GlaxoSmithKline Individual Savings Account

• GlaxoSmithKline Corporate Sponsored Nominee

• Shareview service

• Shareview dealing service

Share dealing service

Hoare Govett operate a postal dealing service in the company’s ordinary shares. It enables investors to buy or sell shares at competitive commission charges. Further details may be obtained by telephoning +44 (0)20 7661 6555.

Glaxo Wellcome and SmithKline Beecham corporate PEPs

The Share Centre Limited
Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ
Tel: +44 (0)1296 414 141

AMERICAN DEPOSITARY SHARES

The company’s shares are listed on the New York Stock Exchange (NYSE) in the form of American Depositary Shares (ADSs) and these are evidenced by American Depositary Receipts (ADRs), each one of which represents two ordinary shares.

In general, the NYSE’s rules permit the company to follow UK corporate governance practices instead of those that apply in the US, provided that the company explains any significant variations. This explanation is provided on the company’s website.

ADR programme administrator

The ADR programme is administered by:

The Bank of New York
Shareholder Relations
PO Box 11258, Church Street Station
New York NY 10286-1258
www.adrbny.com
Tel:1 877 353 1154 toll free
Tel: +1 212 815 3700 outside the USA

Customer Response Center

Tel: 1 888 825 5249 toll free

The administrators also provide Global BuyDIRECT, a direct ADS purchase/sale and dividend reinvestment plan for ADR holders.

The provision of the details on this page is not intended to be an invitation or inducement to engage in an investment activity. Advice on share dealing should be obtained from a stockbroker or independent financial adviser.